CTLA4 and melanoma: While most TCGA datasets were from non-immunotherapy-treated cohorts, two datasets contained immunotherapy-exposed patients: TCGA-SKCM (melanoma; 24 patients) and TCGA-BLCA (urothelial cancer; two patients), both treated with anti-PD-1/CTLA-4.